Erratum: Alzheimer's Aß peptides with disease-associated N-terminal modifications: Influence of isomerisation, truncation and mutation on Cu 2+ coordination (PLoS ONE (2010) 5, 12 (e15875) DOI: 10.1371/journal.pone.0015875);Alzheimer's Aβ peptides with disease-associated NTerminal modifications: Influence of isomerisation, truncation and mutation on Cu2+ coordination

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Drew, Simon C ^a,b,c,d   Masters, Colin L ^a   Barnham, Kevin J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MAX PLANCK INSTITUTE FOR CHEMICAL ENERGY CONVERSION   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[3-16]; COPPER ION; UNCLASSIFIED DRUG; COPPER; GLUTAMIC ACID; LIGAND;

AMINO TERMINAL SEQUENCE; ARTICLE; CHELATION; ELECTRON SPIN RESONANCE; HYDROGEN BOND; ISOMERIZATION; ISOTOPE LABELING; MUTATIONAL ANALYSIS; PH; PROTEIN CLEAVAGE; PROTEIN MODIFICATION; ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DISEASE COURSE; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; OXIDATION REDUCTION REACTION; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; STEREOISOMERISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COPPER; DISEASE PROGRESSION; ELECTRON SPIN RESONANCE SPECTROSCOPY; GLUTAMIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; MICE; MUTATION; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; STEREOISOMERISM;

EID: 78651247095     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102192     Document Type: Erratum

References (68)

1. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.
2. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52.
3. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, et al. (2002) Metalloenzyme-like activity of Alzheimer's disease β-amyloid. J Biol Chem 277: 40302-40308.
4. Bush AI (2003) Copper, zinc, and the metallobiology of Alzheimer disease. Alz Dis Assoc Disord 17: 147-150.
5. Barnham KJ, Bush AI (2008) Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 12: 222-228.
6. Balland V, Hureau C, Saveant JM (2010) Electrochemical and homogeneous electron transfers to the Alzheimer amyloid-beta copper complex follow a preorganization mechanism. Proc Natl Acad Sci U S A 107: 17113-17118.
7. + Binding in the 1-16 Region of the Amyloid-beta Peptide Involved in Alzheimer's Disease. J Phys Chem B 114: 15119-15133.
8. Jiang D, Li X, Liu L, Yagnik GB, Zhou F (2010) Reaction rates and mechanism of the ascorbic acid oxidation by molecular oxygen facilitated by Cu(II)- containing amyloid-beta complexes and aggregates. J Phys Chem B 114: 4896-4903.
9. 2+ ions accelerate the kinetics of fibre formation and promote cell toxicity of amyloidbeta from Alzheimer's disease. J Biol Chem. doi:10.1074/jbc.M110.171355.
10. Selkoe DJ (2008) Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav Brain Res 192: 106-113.
11. 2+ inhibits the aggregation of amyloid β-peptide (1-42) in vitro. Angew Chem Int Ed 40: 2274-2277.
12. Innocenti M, Salvietti E, Guidotti M, Casini A, Bellandi S, et al. (2010) Trace copper(II) or zinc(II) ions drastically modify the aggregation behavior of amyloid-β1-42: An AFM study. J Alzheimer's Dis 19: 1323-1329.
13. Jun S, Gillespie JR, Shin B, Saxena S (2009) The second Cu(II)-binding site in a proton-rich environment interferes with the aggregation of amyloid-b (1-40) into amyloid fibrils. Biochemistry 48: 10724-10732.
14. Garai K, Sengupta P, Sahoo B, Maiti S (2006) Selective destabilization of soluble amyloid β oligomers by divalent metal ions. Biochem Biophys Res Commun 345: 210-215.
15. Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ (2009) Pleomorphic copper coordination by Alzheimer's disease amyloid-β peptide. J Am Chem Soc 131: 1195-1207.
16. 2+ coordination of Alzheimer's disease amyloid-β peptide - relevance to N-terminally truncated forms. J Am Chem Soc 131: 8760-8761.
17. Dorlet P, Gambarelli S, Faller P, Hureau C (2009) Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-β peptide: A key role of the first two N-terminus residues. Angew Chem Int Ed 48: 9273-9276.
18. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245-4249.
19. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, et al. (1985) Neuronal origin of a cerebral amyloid: neurofibriliary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4: 2757-2763.
20. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 267: 17062-17086.
21. N3(pE), in senile plaques. Neuron 14: 457-466.
22. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ (1996) Full-length amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques. Am J Pathol 149: 1823-1830.
23. Hosoda R, Saido TC, Otvos LJ, Arai T, Mann DM, et al. (1998) Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol 57: 1089-1095.
24. Harigaya Y, Saido TC, Eckman CB, Prada C-M, Shoji M, et al. (2000) Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276: 422-427.
25. Güntert A, Döbeli H, Bohrmann B (2006) High sensitivity analysis of amyloidbeta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neurosci 143: 461-475.
26. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, et al. (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27: 10957-10968.
27. Cummins PM, O'Connor B (1998) Pyroglutamyl peptidase: an overview of the three known enzymatic forms. Biochim Biophys Acta 1429: 1-17.
28. Youssef I, Florent-Béchard S, Malaplate-Armand C, Koziel V, Bihain B, et al. (2008) N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 29: 1319-1333.
29. Russo C, Violani E, Salis S, Venezia V, Dolcini V, et al. (2002) Pyroglutamatemodified amyloid β-peptides - AβN3(pE) - strongly affect cultured neuron and astrocyte survival. J Neurochem 82: 1480-1489.
30. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, et al. (2009) Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 117: 85-96.
31. 3-42. J Biol Chem 284: 22697-22702.
32. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Böhm G, Demuth HU (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45: 12393-12399.
33. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, et al. (1993) Structural alterations in the peptide backbone of β-Amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268: 3072-3083.
34. Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T (2000) Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch Biochem Biophys 381: 225-234.
35. Stephenson RC, Clarke S (1989) Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem 264: 6164-6170.
36. Zirah S, Kozin SA, Mazur AK, Blond A, Cheminant M, et al. (2006) Structural changes of region 1-16 of the Alzheimer disease amyloid β-peptide upon zinc binding and in vitro aging. J Biol Chem 281: 2151-216.
37. Fabian H, Szendrei GI, Mantsch HH, Greenberg BD, Ötvös L, Jr. (1994) Synthetic post-translationally modified human AB peptide exhibits a markedly increased tendency to form β-pleated sheets in vitro. Eur J Biochem 221: 959-964.
38. Tsvetkov PO, Popov IA, Nikolaev EN, Archakov AI, Makarov AA, et al. (2008) Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid β(1-16) peptide. ChemBioChem 9: 1564-1567.
39. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, et al. (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323: 1473-1477.
40. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5: 421-432.
41. Hanson GR, Gates KE, Noble CJ, Griffin M, Mitchell A, et al. (2004) XSophe- Sophe-XeprView®. A computer simulation software suite (v. 1.1.3) for the analysis of continuous wave EPR spectra. J Inorg Biochem 98: 903-916.
42. Schweiger A, Jeschke G (2001) Principles of pulse electron paramagnetic resonance. Oxford: Oxford University Press. 578 p.
43. Sugiura Y, Hirayama Y, Tanaka H, Ishizu K (1975) Copper(II) complex of sulfur-containing peptides. Characterization and similarity of electron spin resonance spectrum to the chromophore in blue copper proteins. J Am Chem Soc 97: 5577-5581.
44. 2- scavenger activity: Cu(II)-peptide complexes as superoxide dismutase models. J Inorg Biochem 73: 157-165.
45. Peisach J, Blumberg WE (1974) Structural implications derived from the analysis of EPR spectra of natural and artificial copper proteins. Arch Biochem Biophys 165: 691-698.
46. Deligiannakis Y, Louloudi M, Hadjiliadis N (2000) Electron spin echo envelope modulation (ESEEM) spectroscopy as a tool to investigate the coordination environment of metal centers. Coord Chem Rev 204: 1-112.
47. Drew SC, Djoko KY, Zhang L, Koay M, Boas JF, et al. (2008) Electron paramagnetic resonance characterization of the copper-resistance protein PcoC from Escherichia coli. J Biol Inorg Chem 13: 899-907.
48. 2+ binding sites in the C-terminal domain of the murine prion protein: A pulse EPR and ENDOR study. J Phys Chem B 105: 1631-1639.
49. Van Doorslaer S, Sierra GA, Schweiger A (1999) Dead time-dependent line distortions in absolute-value electron spin echo envelope modulation spectra. J Magn Reson 136: 152-158.
50. 2+ binding site in amyloid-β. Biochemistry 44: 5478-5787.
51. Karr JW, Szalai VA (2007) Role of aspartate-1 in Cu(II) binding to the amyloidb peptide of Alzheimer's disease. J Am Chem Soc 129: 3796-3797.
52. Miura T, Mitani S, Takanashi C, Mochizuki N (2004) Copper selectively triggers β-sheet assembly of an N-terminally truncated amyloid β-peptide beginning with Glu3. J Inorg Biochem 98: 10-14.
53. Kumar S, Nussinov R (2002) Close range electrostatic interactions in proteins. ChemBioChem 3: 604-617.
54. Lou Y-C, Huang Y-C, Pan Y-R, Chen C, Liao Y-D (2006) Roles of N-terminal pyroglutamate in maintaining structural integrity and pKa values of catalytic histidine residues in bullfrog ribonuclease 3. J Mol Biol 355: 409-421.
55. Fischer WH, Spiess J (1987) Identification of a mammalian glutarminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc Nat Acad Sci U S A 84: 3628-3632.
56. Cynis H, Schilling S, Bodnár M, Hoffmann T, Heiser U, et al. (2006) Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochem Biophys Acta - Proteins and Proteomics 1764: 1618-1625.
57. Sevalle J, Amoyel A, Robert P, Fournié-Zaluski M-C, Roques B, et al. (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid β-peptide. J Neurochem 109: 248-256.
58. McDermott JR, Mantle D, Lauffart B, Kidd AM (1985) Purification and characterization of a neuropeptide-degrading aminopeptidase from human brain. J Neurochem 45: 752-759.
59. Mantle D, Perry EK (1990) Comparison of aminopeptidase, dipeptidyl aminopeptidase and tripeptidyl aminopeptidase activities in brain tissue from normal and Alzheimer's disease cases. J Neurol Sci 98: 13-20.
60. Kowalik-Jankowska T, Ruta M, Wiśniewska K, Łankiewicz L (2003) Coordination abilities of the 1-16 and 1-28 fragments of β-amyloid peptide towards copper(II) ions: a combined potentiometric and spectroscopic study. J Inorg Biochem 96: 270-282.
61. Kowalik-Jankowska T, Ruta M, Wiśniewska K, Łankiewicz L, Dyba M (2004) Products of Cu(II)-catalyzed oxidation in the presence of hydrogen peroxide of the 1-10, 1-16 fragments of human and mouse β-amyloid peptide. J Inorg Biochem 98: 940-950.
62. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JDA, et al. (1999) Cu(II) Potentiation of Alzheimer Aβ Neurotoxicity. J Biol Chem 274: 37111-37116.
63. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D (2002) Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32: 1076-1083.
64. Sayre LM (1986) Metal ion catalysis of amide hydrolysis. J Am Chem Soc 108: 1632-1635.
65. Fife TH, Przystas TJ (1986) Divalent metal ion catalysis in amide hydrolysis. The hydrolysis of N-acylimidazoles. J Am Chem Soc 108: 4631-4636.
66. Blumberger J, Lamoureux G, Klein ML (2007) Peptide hydrolysis in thermolysin: ab initio QM/MM investigation of the Glu143-assisted water addition mechanism. J Chem Theory Comput 3: 1837-1850.
67. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, et al. (2003) Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42: 2768-2773.
68. Duerr BF, Czarnik AW (1990) Copper(II)-catalysed hydrolysis of an unactivated amide. Application of the Groves' rule to the hydrolysis of acrylamide. J Chem Soc Chem Comm. pp 1707-1709.